We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma.
- Authors
Vandyke, Kate; Chow, Annie W.S.; Williams, Sharon A.; To, Luen B.; Zannettino, Andrew C.W.
- Abstract
N-cadherin (cadherin 2, type 1, N-cadherin (neuronal); CDN2) is a homotypic adhesion molecule that is upregulated in breast, prostate and bladder cancer. Here we investigated the prognostic significance of upregulated N-cadherin expression in multiple myeloma ( MM). Our results indicate that N-cadherin protein and gene expression is abnormally increased in trephine biopsies and CD38++/ CD138+ plasma cells from MM patients, when compared with those of normal donors. In addition, levels of circulating N-cadherin were elevated in a subset of patients with MM ( n = 81; mean: 14·50 ng/ml, range: 0-146·78 ng/ml), relative to age-matched controls ( n = 27; mean: 2·66 ng/ml, range: 0-5·96 ng/ml), although this did not reach statistical significance. Notably, patients with abnormally high levels of N-cadherin (>6 ng/ml) had decreased progression-free survival ( P = 0·036; hazard ratio: 1·94) and overall survival ( P = 0·002; hazard ratio: 3·15), when compared with patients with normal N-cadherin levels (≤6 ng/ml). Furthermore, multivariate analyses revealed that the combination of N-cadherin levels and International Staging System ( ISS) was a more powerful prognostic indicator than using ISS alone. Collectively, our studies demonstrate that circulating N-cadherin levels are a viable prognostic marker for high-risk MM patients.
- Subjects
MULTIPLE myeloma diagnosis; CADHERINS; PROGNOSTIC tests; CELL adhesion molecules; GENE expression; HEALTH risk assessment
- Publication
British Journal of Haematology, 2013, Vol 161, Issue 4, p499
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.12280